Ethyl Acetate

Ethyl Acetate

SCHEMBL8314224

CCOC(C)=O.ClC(Cl)C(Cl)Cl

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.74
LMNA P02545 1/20 0.74
HSD17B10 Q99714 1/20 0.74
TSHR P16473 1/20 0.46
ALOX15 P16050 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
SOAT1 P35610 1/20 0.42
TRPA1 O75762 1/20 0.39
GLO1 Q04760 1/20 0.38
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 3/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL16107062 1.00 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL8479264 0.95 ALDH1A1 (0.67) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL8740178 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL1715654 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL5413296 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL10364372 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL1392317 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL5861946 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL6268192 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15
Ethyl Acetate SCHEMBL11181789 0.92 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111886219-B Immunosuppressant, preparation method and pharmaceutical application thereof 上海和誉生物医药科技有限公司 2023-04-25 CN disclosed
CN-111886219-A Immunosuppressant, preparation method and pharmaceutical application thereof 上海和誉生物医药科技有限公司 2020-11-03 CN disclosed
CN-110461841-B Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof 上海和誉生物医药科技有限公司 2020-09-15 CN disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 US disclosed
CN-110461841-A A kind of azepine aryl derivatives, preparation method and application with CSF1R inhibitory activity ABBISKO THERAPEUTICS CO LTD 2019-11-15 CN disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 US disclosed
CN-106459463-A Method for producing polyaniline composite composition, and polyaniline composite composition 出光兴产株式会社 2017-02-22 CN disclosed
US-20140231772-A1 MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME IDEMITSU KOSAN CO., LTD. 2014-08-21 US disclosed
EP-0536419-B1 TRICYCLIC TRIAZOLE DERIVATIVES, PRODUCTION AND USE THEREOF TORAY INDUSTRIES (JP) 1999-10-13 EP disclosed
US-5683998-A ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIPAF AGENTS TORAY INDUSTRIES, INC. (JP) 1997-11-04 US disclosed
US-5599823-A HYPOTENSIVE AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1997-02-04 US disclosed
EP-0536419-A1 TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 1993-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 ALDH1A1 1708/4885LMNA 4846/4885HSD17B10 3262/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 ALDH1A1 1708/4885LMNA 4846/4885HSD17B10 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.